La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Innovent Biologics Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Innovent Biologics ha un patrimonio netto totale di CN¥12.5B e un debito totale di CN¥3.5B, che porta il suo rapporto debito/patrimonio netto a 28.1%. Le sue attività totali e le sue passività totali sono rispettivamente CN¥20.6B e CN¥8.1B.

Informazioni chiave

28.1%

Rapporto debito/patrimonio netto

CN¥3.52b

Debito

Indice di copertura degli interessi	n/a
Contanti	CN¥10.97b
Patrimonio netto	CN¥12.53b
Totale passività	CN¥8.10b
Totale attività	CN¥20.63b

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

Shareholders May Not Be So Generous With Innovent Biologics, Inc.'s (HKG:1801) CEO Compensation And Here's Why

Jun 14

Innovent Biologics, Inc. (HKG:1801) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

May 01

There's Reason For Concern Over Innovent Biologics, Inc.'s (HKG:1801) Massive 27% Price Jump

Feb 28

Are Investors Undervaluing Innovent Biologics, Inc. (HKG:1801) By 33%?

Jan 12

Innovent Biologics, Inc.'s (HKG:1801) Price Is Out Of Tune With Revenues

Dec 25

An Intrinsic Calculation For Innovent Biologics, Inc. (HKG:1801) Suggests It's 34% Undervalued

Sep 11

Is There An Opportunity With Innovent Biologics, Inc.'s (HKG:1801) 50% Undervaluation?

Jun 04

Benign Growth For Innovent Biologics, Inc. (HKG:1801) Underpins Its Share Price

May 14

Innovent Biologics, Inc. (HKG:1801) Shares Could Be 50% Below Their Intrinsic Value Estimate

Dec 27

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( CN¥13.4B ) di 1801 superano le sue passività a breve termine ( CN¥4.5B ).

Passività a lungo termine: Le attività a breve termine di 1801 ( CN¥13.4B ) superano le sue passività a lungo termine ( CN¥3.6B ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: 1801 ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di 1801 è aumentato da 18.9% a 28.1% negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: 1801 ha una cash runway sufficiente per più di 3 anni in base al suo attuale free cash flow.

Previsione Cash Runway: Dati insufficienti per determinare se 1801 ha una sufficiente pista di cassa se il suo flusso di cassa libero continua a crescere o a ridursi in base ai tassi storici.

Innovent Biologics Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Innovent Biologics, Inc. Announces the Approval of Dupert® (Fulzerasib) by the National Medical Products Administration of China

The National Medical Products Administration Approves Centre for Drug Evaluation of the National Medical Products Administration of China's First KRAS G12C Inhibitor Dupert

Innovent Biologics, Inc. to Report First Half, 2024 Results on Aug 28, 2024

Innovent Biologics, Inc. and Sanegene Bio USA Inc. Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3016 (AGT siRNA)

the National Medical Products Administration of China Accepts the New Drug Application of Mazdutide of Innovent Biologics, Inc

Innovent Biologics, Inc. Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA's 84th Scientific Sessions

Shareholders May Not Be So Generous With Innovent Biologics, Inc.'s (HKG:1801) CEO Compensation And Here's Why

High number of new directors

Innovent Biologics, Inc. Announces Picankibart (IBI112) Achieved Primary Endpoints in A Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to the NDA to the NMPA

Innovent Biologics Announces National Medical Products Administration of China Accepts the New Drug Application for IBI311

Co-Founder recently sold HK$37m worth of stock

Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer

Innovent Biologics, Inc. (HKG:1801) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Full year 2023 earnings released: CN¥0.66 loss per share (vs CN¥1.46 loss in FY 2022)

Innovent Biologics, Inc. Appoints Samuel Zhang as Global Chief Business Officer

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

Innovent Biologics, Inc. Announces the National Medical Products Administration Accepts the New Drug Application

Innovent Biologics, Inc., Annual General Meeting, Jun 21, 2024

Full year 2023 earnings released: CN¥0.66 loss per share (vs CN¥1.46 loss in FY 2022)

Now 20% undervalued

Innovent Biologics, Inc. Releases the Results of Two Clinical Studies of Ibi311 (An Anti-IGF-1R Monoclonal Antibody) in Oral Presentations At the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024

Anheart Therapeutics and Innovent Announces China’s NMPA Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of Ros1-Positive Lung Cancer

Now 25% undervalued after recent price drop

Innovent Biologics, Inc. to Report Fiscal Year 2023 Results on Mar 20, 2024

There's Reason For Concern Over Innovent Biologics, Inc.'s (HKG:1801) Massive 27% Price Jump

Innovent Biologics, Inc. Announces the Phase 3 Clinical Study of Ibi311 Met the Primary Endpoint in Treating Thyroid Eye Disease

Forecast to breakeven in 2025

Innovent Biologics, Inc. Announces Appointment of Shun Lu as Independent Non-Executive Director and A Member of the Strategy Committee

Innovent Biologics, Inc.'s First New Drug Application of Mazdutide for Chronic Weight Management Has Been Accepted by the NMPA of China

Innovent Biologics, Inc. Announces Chief Financial Officer Changes

Innovent Biologics, Inc. Announces Chief Financial Officer Changes

Are Investors Undervaluing Innovent Biologics, Inc. (HKG:1801) By 33%?

Innovent Biologics, Inc. Announces the First Phase 3 Clinical Trial of Mazdutide Inchinese Adults with Overweight or Obesity Metthe Primary and All Key Secondary Endpoints

Innovent Biologics, Inc.'s (HKG:1801) Price Is Out Of Tune With Revenues

China’S National Medical Products Administration Grants Anheart Therapeutics and Innovent Biologics, Inc. Taletrectinib (Ros1 Inhibitor) Priority Review Designation for the New Drug Application (Nda) of Taletrectinib

Innovent Biologics, Inc. Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications

Innovent Biologics, Inc. Announces the Phase 3 Orient-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Innovent Biologics, Inc. Announces the National Medical Products Administration of China Accepts and Grants Priority Review Designation to the New Drug Application for IBI351

Innovent Biologics, Inc. Announces Acceptance of New Drug Application from National Medical Products Administration for Taletrectinib

Innovent Biologics, Inc Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Type 2 Diabetes in Diabetes Care

The National Medical Products Administration Approves Olverembatinib for the Treatment of Cml-Cp Patients

Now 20% undervalued

Innovent Biologics, Inc. Announces Robust Weight Loss Efficacy, Multiple Metabolic Benefits and Favorable Safety Profile of Higher Dose 9 mg Mazdutide (IBI362) after 48-week Treatment in Phase 2 Study for Obesity

Innovent Biologics, Inc. Announces Update on the New Drug Application for Parsaclisib (PI3Kd Inhibitor)

Innovent Biologics, Inc. has completed a Follow-on Equity Offering in the amount of HKD 2.35688 billion.

An Intrinsic Calculation For Innovent Biologics, Inc. (HKG:1801) Suggests It's 34% Undervalued

First half 2023 earnings: EPS and revenues exceed analyst expectations

National Medical Products Administration Approves New Drug Application for Innovent Biologics, Inc.'s Sintbilo

Innovent Biologics, Inc. to Report Q2, 2023 Results on Aug 23, 2023

IASO Bio and Innovent Announce the NMPA Approval of the New Drug Application for Equecabtagene Autoleucel, the World's First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed and/or Refractory Multiple Myeloma

Innovent Biologics, Inc. Announces Phase 1 Clinical Data of IBI322 (CD47/PD-L1 Bispecific Antibody) in the Treatment of Anti-PD-(L)1-Resistant Classic Hodgkin Lymphoma Patients at the EHA 2023 Annual Meeting

Innovent Presents Phase 1 Clinical Data of IBI351 as Monotherapy for Metastatic Colorectal Cancer at the 2023 ASCO Annual Meeting

Innovent Updates Phase 1B Data of IbI939 (Anti-Tigit Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-Selected NSCLC

Is There An Opportunity With Innovent Biologics, Inc.'s (HKG:1801) 50% Undervaluation?

Innovent Announces the Second Breakthrough Therapy Designation by NMPA for Olverembatinib for the Treatment of Patients with SDH-Deficient GIST

Benign Growth For Innovent Biologics, Inc. (HKG:1801) Underpins Its Share Price

Innovent Biologics, Inc. Announces Phase 2 Clinical Study of Higher dose 9 mg Mazdutide (IBI362) in Chinese Adults with Obesity Achieved the 24-Week Primary Endpoint

Innovent Biologics, Inc. Announces National Medical Products Administration Approves TYVYT (Sintilimab Injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-Mutated Non-Squamous Nsclc Who Progressed After EGFR-TKI Therapy

Now 22% undervalued

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Innovent Announces First Patient Dosed in a Phase 3 Clinical Trial (CLEAR) of Picankibart (Anti-IL23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Plaque Psoriasis

Innovent Biologics, Inc. Announces First Participant Dosed in Phase 2 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Associated Ophthalmopathy

Innovent Announces Inclusion in the China National Reimbursement Drug List (NRDL) of TYVYT in Two New Indications, Olverembatinib for the First Listing, BYVASDA, HALPRYZA and SULINNO in Multiple New Indications

Innovent Biologics, Inc. Announces First Participant Dosed in A Phase 3 Clinical Study (Dreams-1) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes

Innovent Biologics, Inc. Announces the National Medical Products Administration in China Has Accepted and Granted Priority Review Designation to the New Drug Application for Parsaclisib

Forecast to breakeven in 2025

Innovent Biologics, Inc. (HKG:1801) Shares Could Be 50% Below Their Intrinsic Value Estimate

Innovent Biologics, Inc. Presents Phase Ib Clinical Data Update of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2022 European Society For Medical Oncology Immuno-Oncology Congress

Innovent and UNION Therapeutics Announce First Subject Dosed in a Chinese Clinical Phase I Study of the Novel PDE4 Inhibitor Orismilast (IBI353)

Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (GLORY-1) of Mazdutide (IBI362) in Chinese Adults with Overweight or Obesity

Innovent Biologics, Inc. Releases Results of a Phase 3 Clinical Study of Tafolecimab(IBI306)in Chinese Patients with non- Familial Hypercholesterolemia at the American Heart Association (AHA) Scirntific Sessions 2022

Innovent Announces First Patient Dosing in Australia in Phase I Study of IBI343 (Recombinant anti-Claudin18.2 Monoclonal Antibody-drug Conjugate) in Patients with Advanced Solid Tumors

Innovent Announces Phase Ib Results of Higher-Dose Mazdutide (IBI362) in Chinese Participants with Overweight or Obesity Published in eClinicalmedicine

Innovent Announces Phase Ib Results of Higher-Dose Mazdutide (IBI362) in Chinese Participants with Overweight or Obesity Published in eClinicalmedicine

Innovent Biologics, Inc. Announces China NMPA Approves CYRAMZA (ramucirumab) for Treatment in Patients with Hepatocellular Carcinoma